Man Group plc Makes New $217,000 Investment in SI-BONE, Inc. (NASDAQ:SIBN)

Man Group plc acquired a new stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 15,454 shares of the company's stock, valued at approximately $217,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SIBN. American Century Companies Inc. lifted its holdings in SI-BONE by 11.0% during the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after purchasing an additional 236,167 shares in the last quarter. Marshall Wace LLP lifted its holdings in SI-BONE by 332.5% during the fourth quarter. Marshall Wace LLP now owns 264,523 shares of the company's stock valued at $3,709,000 after purchasing an additional 203,361 shares in the last quarter. Nuveen Asset Management LLC lifted its holdings in SI-BONE by 17.8% during the fourth quarter. Nuveen Asset Management LLC now owns 1,263,988 shares of the company's stock valued at $17,721,000 after purchasing an additional 190,830 shares in the last quarter. First Eagle Investment Management LLC purchased a new position in SI-BONE during the fourth quarter valued at $2,600,000. Finally, Tocqueville Asset Management L.P. purchased a new position in SI-BONE during the fourth quarter valued at $2,383,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SIBN. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 price objective on shares of SI-BONE in a research note on Tuesday, May 6th. Finally, Truist Financial upped their price objective on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th.

Insider Transactions at SI-BONE

In other news, CEO Laura Francis sold 38,504 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $17.18, for a total value of $661,498.72. Following the transaction, the chief executive officer now directly owns 302,958 shares in the company, valued at approximately $5,204,818.44. This represents a 11.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the transaction, the senior vice president now owns 244,878 shares in the company, valued at approximately $3,462,574.92. This represents a 1.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 92,565 shares of company stock worth $1,669,871. 4.00% of the stock is currently owned by insiders.

SI-BONE Trading Down 0.6%

Shares of SI-BONE stock traded down $0.12 during mid-day trading on Friday, hitting $18.86. The stock had a trading volume of 437,967 shares, compared to its average volume of 378,083. The firm has a 50-day moving average of $15.62 and a two-hundred day moving average of $15.30. SI-BONE, Inc. has a 12-month low of $11.70 and a 12-month high of $20.05. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The firm has a market cap of $803.72 million, a P/E ratio of -20.50 and a beta of 0.82.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The business had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. Sell-side analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.